Countermeasures Against Chemical Threats (CounterACT) Program Early-stage Investigator R21 Q&A Webinar

Countermeasures Against Chemical Threats (CounterACT) Program Early-stage Investigator R21 Q&A Webinar

June 24, 2021
June 24, 2021

Contact: 

Neel Dhruv

Contact Email: 

neel.dhruv@nih.gov

Location: 

Virtual webinar at 4 PM EST

Event Description: 

The Countermeasures Against Chemical Threats (CounterACT) Program is a trans-NIH initiative that supports basic and translational research that improves therapeutic medical countermeasures against chemical threat agents. Additionally, the program facilitates the movement of medical countermeasures through the drug development and regulatory processes in collaboration with other federal departments, agencies, and initiatives.

Dr. Shardell Spriggs, Program Manager in the CounterACT program, will provide an overview of a new funding opportunity designed to recruit Early-stage Investigators (ESI) to pursue programs of interest to the NIH Chemical Countermeasures Research Programs (CCRP). Two unique features of this funding opportunity are that they are funded for three years and applicants are strictly limited to no more than one-half page of preliminary data.

PAR-21-209 NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed). This funding opportunity will have only one receipt date of July 27, 2021

All investigators who are interested in learning about this exciting opportunity and the CounterACT program are encouraged to register and participate. While you can listen to the call on the phone, all questions will need to be submitted online. You can also submit questions before the meeting to Dr. Neel Dhruv.

Post Event Summary: